Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RRM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RRM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RRM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RRM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RRM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RRM1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RRM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000039833 | Oral cavity | NEOLP | mRNA splicing, via spliceosome | 81/2005 | 320/18723 | 7.96e-14 | 2.63e-11 | 81 |
GO:000037533 | Oral cavity | NEOLP | RNA splicing, via transesterification reactions | 81/2005 | 324/18723 | 1.64e-13 | 5.13e-11 | 81 |
GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
GO:000037517 | Prostate | BPH | RNA splicing, via transesterification reactions | 114/3107 | 324/18723 | 2.19e-16 | 4.53e-14 | 114 |
GO:000037717 | Prostate | BPH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:000039817 | Prostate | BPH | mRNA splicing, via spliceosome | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:000838019 | Prostate | Tumor | RNA splicing | 153/3246 | 434/18723 | 9.15e-20 | 5.79e-17 | 153 |
GO:000037518 | Prostate | Tumor | RNA splicing, via transesterification reactions | 119/3246 | 324/18723 | 3.40e-17 | 1.06e-14 | 119 |
GO:000037718 | Prostate | Tumor | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
GO:000039818 | Prostate | Tumor | mRNA splicing, via spliceosome | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
GO:000037526 | Skin | AK | RNA splicing, via transesterification reactions | 85/1910 | 324/18723 | 1.16e-16 | 7.62e-14 | 85 |
GO:000037726 | Skin | AK | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:000039826 | Skin | AK | mRNA splicing, via spliceosome | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:004860819 | Skin | AK | reproductive structure development | 77/1910 | 424/18723 | 3.56e-07 | 1.36e-05 | 77 |
GO:006145820 | Skin | AK | reproductive system development | 77/1910 | 427/18723 | 4.76e-07 | 1.74e-05 | 77 |
GO:000931420 | Skin | AK | response to radiation | 78/1910 | 456/18723 | 3.32e-06 | 8.59e-05 | 78 |
GO:00309006 | Skin | AK | forebrain development | 66/1910 | 379/18723 | 1.02e-05 | 2.17e-04 | 66 |
GO:001021210 | Skin | AK | response to ionizing radiation | 29/1910 | 148/18723 | 4.27e-04 | 4.05e-03 | 29 |
GO:00613513 | Skin | AK | neural precursor cell proliferation | 26/1910 | 145/18723 | 3.08e-03 | 1.92e-02 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RRM1 | SNV | Missense_Mutation | | c.613N>T | p.Leu205Phe | p.L205F | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
RRM1 | SNV | Missense_Mutation | novel | c.1880N>A | p.Arg627His | p.R627H | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.941) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | novel | c.562N>C | p.Glu188Gln | p.E188Q | P23921 | protein_coding | tolerated_low_confidence(0.09) | benign(0.125) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | | c.7N>T | p.Val3Leu | p.V3L | P23921 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.87) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
RRM1 | SNV | Missense_Mutation | | c.251N>G | p.Ser84Cys | p.S84C | P23921 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.729) | TCGA-D8-A1XS-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
RRM1 | deletion | Frame_Shift_Del | novel | c.1415delN | p.Val472AlafsTer6 | p.V472Afs*6 | P23921 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RRM1 | SNV | Missense_Mutation | novel | c.739N>A | p.Gly247Arg | p.G247R | P23921 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.908) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RRM1 | SNV | Missense_Mutation | | c.979G>T | p.Asp327Tyr | p.D327Y | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | | c.2254N>G | p.Leu752Val | p.L752V | P23921 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RRM1 | SNV | Missense_Mutation | novel | c.2180G>A | p.Gly727Asp | p.G727D | P23921 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.995) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | VINORELBINE | VINORELBINE | 23038758,24647522 |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | MOTEXAFIN GADOLINIUM | | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | CLOFARABINE | CLOFARABINE | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | CHEMBL1200983 | GALLIUM NITRATE | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | CHEMBL1096882 | FLUDARABINE PHOSPHATE | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | CISPLATIN | CISPLATIN | 12917817 |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | cytarabine | CYTARABINE | 24024897 |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | CHEMBL467 | HYDROXYUREA | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | inhibitor | 178103428 | HYDROXYUREA | |
6240 | RRM1 | DRUGGABLE GENOME, ENZYME, DNA REPAIR | | GTI-2501 | | |